Palin Communications has been working with Brisbane-based clinical stage pharma company De Motu Cordis (DMC) to focus attention on its progress in developing a technology for faster epinephrine absorption via inhalation. In the future this may prove to be a valuable alternative delivery mode for serious allergic reactions like anaphylaxis as well as other time critical emergency medicine applications in the community setting.
The Palin team has been working to build global awareness of DMC and its progress among key industry media outlets in the USA, Europe and Australia.
Recent media releases and outreach with identified journalists has focused on new commercial manufacturing partnerships and “watershed” regulatory approvals in the sector.
This work has triggered dozens of editorial reports and hundreds of positive syndicated stories about DMC across key pharmaceutical and business titles like BioPharma Dispatch, Biotech Daily, Yahoo Finance, Associated Press and others.
CEO Peter O’Neill says he is looking forward to building further momentum with this ongoing program as upcoming milestones are met and announced.
“It is very timely for DMC to now be proactive and consistent with our external communications. Our business is making great progress and building our global profile among investors, global pharma and other key commercial stakeholders is imperative ,” said O’Neill.
Comments